openPR Logo
Press release

curasan AG: cooperation agreement for new product line

05-26-2010 09:32 AM CET | Health & Medicine

Press release from: curasan AG

/ PR Agency: fr
Kleinostheim, Germany, 25th May 2010 – curasan AG, listed in the General Standard of the Frankfurt Stock Exchange (ISIN: DE 000 549 453 8), has concluded a contract with Matricel GmbH, Herzogenrath, which secures exclusive rights for both companies over a jointly developed new product line. As manufacturer, Matricel GmbH will supply curasan AG, which in turn holds the marketing rights.

In contrast to the bone augmentation material Cerasorb®, which is composed of pure beta-tricalcium phosphate, the new products are composite materials; i.e. they consist of a combination of Cerasorb® with collagen. With this, alongside the current Cerasorb® granulates and moulded parts, new forms of application are being created, which simplify handling for surgeons and implantologists. Cerasorb® and collagen are completely remodelable in autogenous bone.

The highly purified collagen is obtained by means of a proprietary processing method and is combined with curasan's bioceramics. The composite sponges, which become elastic and absorbent in contact with fluid, are manufactured in various sizes. Their open pore structure permits rapid and deep ingrowth of osteocytes and, thereby, a stable bone remodeling of the implant.

“The combination of our proven, synthetic Cerasorb® ceramic material together with the biological properties of collagen, results in a product line that is a component part of our announced product offensive”, states Hans Dieter Rössler, CEO of curasan AG. “At present we are collecting the data for certification by the notified body. If the approval process goes according to plan, sales can provisionally start during the first half of 2011.”

Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
www.curasan.de

Background information on Matricel GmbH:
Matricel GmbH, Herzogenrath, develops and produces innovative medical devices and starting materials for pharmaceuticals for use in medicine and biotechnology. The main products are class III medical devices produced from collagen, which find application as implants in different fields of regenerative medicine.
www.matricel.de

Press Contact:
curasan AG
Andrea Weidner
Lindigstraße 4
63801 Kleinostheim
Germany
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de

fr financial relations gmbh
Jörn Gleisner
Gutleutstraße 75
60329 Frankfurt/Main
Germany
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release curasan AG: cooperation agreement for new product line here

News-ID: 132961 • Views: 1037

More Releases from curasan AG

curasan AG: Dental Business Unit acquired as of June 1
Kleinostheim, Germany, June 6, 2013 – curasan AG, Germany, has acquired a large part of the “Oral Regenerative Medicine” division of Riemser Pharma GmbH, Germany, effective June 1, 2013. curasan AG now owns the marketing and distribution rights for the products covered by the contract and is assuming the sales structures, including the na-tional and international customer base. As a result of this change, curasan has immediate access to the dental market
curasan AG now sells bone regeneration material in injectable form
Kleinostheim, 05.12.2012 – curasan AG, listed on the General Standard (ISIN: DE 000 549 453 8), has introduced its new bone regeneration material CERASORB® Ortho Paste to the German and European markets at the beginning of December. CERASORB® Ortho Paste is comprised of fine granules of the proven, fully resorbable, synthetic material CERASORB® M Ortho suspended in a hyaluronic acid hydrogel-matrix. The paste-like product has the advantage that it is
curasan AG commences operations in the European market with the appointment of a …
Kleinostheim, 15.02.2012 – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8), created a new post on 1st February 2012 in relation to the active expansion of its European sales network in the fields of Orthopaedics and trauma surgery. Mr. Lee McCann BSc Business Administration (North West University of Applied Science, London, U.K.), will be operating as the organisation’s International Sales Director for Orthobiologics with immediate
curasan AG: Novel bone regeneration material approved for sale in Europe
Kleinostheim, Germany – curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material. Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation. “With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate

All 5 Releases


More Releases for Cerasorb®

curasan AG: Dental Business Unit acquired as of June 1
Kleinostheim, Germany, June 6, 2013 – curasan AG, Germany, has acquired a large part of the “Oral Regenerative Medicine” division of Riemser Pharma GmbH, Germany, effective June 1, 2013. curasan AG now owns the marketing and distribution rights for the products covered by the contract and is assuming the sales structures, including the na-tional and international customer base. As a result of this change, curasan has immediate access to the dental market
curasan AG now sells bone regeneration material in injectable form
Kleinostheim, 05.12.2012 – curasan AG, listed on the General Standard (ISIN: DE 000 549 453 8), has introduced its new bone regeneration material CERASORB® Ortho Paste to the German and European markets at the beginning of December. CERASORB® Ortho Paste is comprised of fine granules of the proven, fully resorbable, synthetic material CERASORB® M Ortho suspended in a hyaluronic acid hydrogel-matrix. The paste-like product has the advantage that it is
curasan AG receives approval for Cerasorb® M ORTHO in Canada
Kleinostheim, Germany – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada. “This news has come as a pleasant surprise”, stated Hans Dieter Rössler, CEO. “Since the approval process for medical devices by the Canadian authorities is highly demanding, we were actually expecting the certification some time
curasan AG: Bioactive bone regeneration material approved for sale in Europe
Kleinostheim, Germany – curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8) has received European approval for its new granular bone regeneration material Ceracell®. Hans Dieter Rössler, CEO of curasan AG, considers the CE-certification of Ceracell® to be another milestone in the implementation of the product offensive launched at the beginning of the year: “We are implementing our strategy of offering innovative
curasan AG: One million units of Cerasorb® produced
Kleinostheim, Germany, 28th April 2010 – The employees of curasan AG awaited the recently produced batch of Cerasorb® M with particular excitement – because amongst this batch was the one millionth bottle ready for sale. Depending on requirements, the bottles contain between 0.5 and 30 grams of the synthetic bone substitute material. The batch was part of a production order placed by Riemser Arzneimittel AG, which has been selling Cerasorb®
curasan AG: New US subsidiary for orthopaedics
Kleinostheim, Germany, 18th February 2010 – curasan AG, listed in the General Standard of the Deutsche Börse AG (ISIN: DE 000 549 453 8), is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States. The newly founded curasan Inc., with its headquarters in Massachusetts, is responsible for commercial and logistical management as well as marketing activities. This occurs in coordination with